Skip to main content
LH logo

LH · Labcorp Holdings Inc.

Track LH — free
$367.90 -0.34 (-0.09%)
Market Cap
$29.90B
Shares
81.20M
Volume · Nov 18 106.73K Avg daily vol (3M) 738.33K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$368.24 Open$372.00 Day$368.07–374.00 52W close$250.39–372.46 Avg vol 30d715K Short int2.5M · 3.1% of shares · 3.0d Short vol68% Last earningsOct 28, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 30

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 10
Investor event
Strong third quarter drives higher guidance

LabCorp reported third-quarter revenue growth of 7%, margin expansion of 60 basis points and adjusted EPS growth of 14.5%, raising full-year revenue guidance by $65 million and adjusted EPS guidance by 18 cents.

2 source passages
So we delivered strong performance in the third quarter, for sure, whereby we grew revenue by 7%, expanded margin by 60 basis points, and grew adjusted EPS by 14.5%. Based on that strength and momentum, we actually raised the midpoint of our guidance ranges for revenue by $65 million and for adjusted EPS by 18 cents. Open the document at this passage
Nov 4
Current report 8-K
Julia Wang to speak at UBS healthcare conference

Labcorp Holdings Inc. said Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET.

Regulation FD disclosure
Source passage
Labcorp Holdings, Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET. Open the document at this passage
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 6.9% in third quarter

Labcorp reported revenue of $3,810.0 million for the three months ended September 30, 2026, up 6.9% from $3,563.5. Revenue for the nine months reached $11,078.7 million, up 6.2%, while operating cash flow rose to $1,200.8 million.

Revenue $3.81B ▲ 6.9% Net income $262.8M ▲ 0.7% Diluted EPS $3.22 ▲ 3.2%
Read from the MD&A section
3 source passages
For the three months ended September 30, 2026, the Company’s revenues were $3,810.0, an increase of 6.9% from $3,563.5 for the corresponding period in 2025. For the nine months ended September 30, 2026, the Company’s revenues were $11,078.7, an increase of 6.2% from $10,435.9 for the corresponding period in 2025. During the nine months ended September 30, 2026, the Company’s operations provided $1,200.8 of cash, as compared to $1,026.3 during the same period in 2025. Open the document at this passage
Oct 28
Earnings call
Q3 2026 earnings call

LabCorp reported third-quarter revenue of $3.8 billion, up 6.9%, and adjusted EPS of $4.78, up 14.5%. It raised its full-year 2026 adjusted EPS guidance to $18.30 to $18.70.

Oct 28
Current report 8-K
Financial results

Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9%, and adjusted EPS of $4.78, up 14.5%. It raised 2026 revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance to $18.30 to $18.70.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$14.59B
Trailing 12 months
Net income (TTM)
$1.00B
Trailing 12 months
Revenue growth YoY
+6.9%
Year over year
Operating margin
10.3%
Trailing 12 months
P / E (TTM)
30.2
Trailing earnings · reciprocal yield 3.3%
FCF yield
4.3%
TTM · current market cap
Return on invested capital
8.5%
Trailing 12 months
Net cash
−$5.59B
Latest balance sheet
Dividend yield
0.8%
Trailing 12 months
Shares change YoY
-2.5%
Year over year · fewer shares
Price change (1Y)
+40.9%
Trailing year
Short interest
3.1%
Latest settlement · 3.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 28, 2026
Q3 FY26

TL;DR. Labcorp reported 6.9% revenue growth, 14.5% adjusted EPS growth and 60 basis points of adjusted operating-margin expansion, raised full-year guidance, and delivered growth and margin expansion in Diagnostics and Biopharma Laboratory Services amid acquisition and specialty-testing activity. PAMA is expected to create an approximately $125 million impact in 2027, while ACA was a 30-basis-point diagnostic-volume headwind, foreign currency’s benefit to guidance was lower than previously expected, and GAAP operating margin contracted 60 basis points.

Bullish
  • + Labcorp raised its full-year 2026 enterprise revenue growth guidance to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70.
  • + Labcorp announced or closed four transactions expected to be accretive to adjusted EPS in year one and to return cost of capital by year three.
Bearish
  • − The proposed PAMA payment cuts threaten patient access, patient care, innovation and laboratory viability.
  • − ACA changes reduced third-quarter diagnostic volume by approximately 30 basis points, with a similar impact expected in the fourth quarter.
  • − An approximately $10 million incremental foreign-currency headwind versus prior guidance constrained the otherwise stronger revenue outlook.
  • − Third-quarter GAAP operating margin contracted 60 basis points to 10.6%.
  • − Planned capital-expenditure increases partially offset the year-over-year improvement in free cash flow.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very Low
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg +11%
above
RSI (14) 65
neutral
MACD trend Negative
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +14%
trailing
6-month return +40%
trailing
YTD return +47%
this year
Relative strength +43%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $331 › 200d $293 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +116 funds added
Insider flow Distributing
Net -$1.3M over 90 days · 100% sells
Short interest Falling
3.13% of shares out · ▼ -0.5% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,082 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +7%
Y/Y
Gross margin 29%
expanding
EPS growth +18%
Y/Y
Free cash flow $1.2B
Valuation P/E 30.2
below peers
Buyback $1.4B
remaining
Balance sheet $5.1B
net debt
Quant / Vol
risk profile
Very Low
Volatility 24%
annualized · 1-yr
Max drawdown −14%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jul 30, 2026
full-year 2026
Enterprise revenue 5.4% – 6.3%
Diagnostic segment revenue 5.3% – 6%
BLS segment revenue 5.5% – 6.5%
Adjusted EPS Non-GAAP $18.10 – $18.65
Capital expenditures as a percentage of revenue 4%
Full-year adjusted tax rate Non-GAAP Maintained 23%
Feb 17, 2026 23% changed to Jul 30, 2026 23%
full year 2026
Free cash flow Maintained $1.24B – $1.36B
Feb 17, 2026 $1.24B – $1.36B changed to Jul 30, 2026 $1.24B – $1.36B
Previous outlook earlier release · from the 8-K filed Apr 30, 2026

Still-open targets the latest release did not restate under the same label.

Revenue Growth, Biopharma Laboratory Services · 2026 Guidance 3.8% – 5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
65 Neutral
MACD trend
Negative Bearish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $331 › 200d $293 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +116 funds added
Insider flow Distributing
Net -$1.3M over 90 days · 100% sells
Short interest Falling
3.13% of shares out · ▼ -0.5% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,082 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $250 Now $368 · 97% Range high $372
vs 200-day avg +26% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
BLS segment operating margin 17% the three months ended June 30, 2026 filing —
Dx segment operating margin 18% the three months ended June 30, 2026 filing —
Adjusted EPS non-GAAP $4.99 Q2 2026 —
Adjusted Operating Income non-GAAP $1.1B Six Months Ended June 30, 2026 —
AOI as % of Revenue non-GAAP 15.8% Q2 2026 —
Backlog $8.73B As of June 30, 2026 —
Capital Expenditures $131.6M Q2 2026 —
Free Cash Flow non-GAAP $384.4M Six Months Ended June 30, 2026 —
Next Twelve Months Forecast Backlog Conversion $2.75B As of June 30, 2026 —
Operating Cash Flow $445.5M Q2 2026 —
TTM Book to Bill 1.03 As of June 30, 2026 —
TTM Net Orders $3.32B As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LH
Labcorp Holdings Inc.
this stock
$29.90B +46.8% +7.2% 30.2 3.1%
TMO
Thermo Fisher Scientific Inc.
$254.47B +18.5% +14.5% 36.2 1.3%
DHR
Danaher Corp
$158.84B -1.4% +8.5% 36.9 1.2%
IDXX
Idexx Laboratories Inc
$54.38B +2.0% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$48.55B +26.6% +6.4% 33.9 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,082
% held
95.0%
Net QoQ
-2.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
752
View
Short & Settlement
Short Interest Falling
Shares short
2.5M
Days to cover
3.0d
Change
-13.2K sh
View
Short Volume
Short vol %
68%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
9.8K
Value
$3.2M
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
40.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.3M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
April McClain Delaney
Amount
$100.0K–$250.0K
Traded
Aug 25, 2026
View
Financials
Financials
Revenue (FY)
$14.0B
Net income (FY)
$876.5M
EPS diluted
$10.46
View
Buybacks
Remaining
$1.4B
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
35

LabCorp reported third-quarter revenue growth of 7%, margin expansion of 60 basis points and adjusted EPS growth of 14.5%, raising full-year revenue guidance by $65 million and adjusted EPS guidance by 18 cents.

View
Proposed Sales
Value
$136.0K
Shares
365
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Labcorp Completes Acquisition of…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
LH -0.7% +14.0% +40.2% +1.9% +46.8%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +1.6% +18.7% +43.1% +5.0% +39.4%

Capital returns

Latest dividend
$0.72 / share · ex Aug 28, 2026
Declared · upcoming
$0.72 / share · ex Nov 24, 2026
Raised 16.4%
Paid (TTM)
$2.88 / share · 4 payouts
Dividend yield (TTM, derived)
0.78%
Full dividend history
Buyback program · as of Oct 28, 2026
Authorized
—
Spent (derived)
—
Remaining
$1.40B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 920148 CUSIP 504922105 13F (30d) 1020 filings 956 filers Visit website Investor relations